aq4n profile

AQ4N: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	9955116
CHEMBL ID	117391
SCHEMBL ID	3676563
MeSH ID	M0248799

Synonym
136470-65-0
aq4n
banoxantrone
CHEMBL117391
aq-4n
1,4-bis(2-(dimethylazinoyl)ethylamino)-5,8-dihydroxy-9,10-anthraquinone
unii-w5h7e45yt3
banoxantrone [inn:ban]
w5h7e45yt3 ,
9,10-anthracenedione, 1,4-bis((2-(dimethyloxidoamino)ethyl)amino)-5,8-dihydroxy-
1,4-bis((2-(dimethylamino)ethyl)amino)-5,8-dihydroxy-9,10-anthracenedione n,n'-dioxide
9,10-anthracenedione, 1,4-bis((2-(dimethylamino)ethyl)amino)-5,8-dihydroxy-, n,n'-dioxide
NCGC00346890-01
9,10-anthracenedione, 1,4-bis[[2-(dimethyloxidoamino)ethyl]amino]-5,8-dihydroxy-
1,4-bis[[2-(dimethyloxidoamino)ethyl]amino]-5,8-dihydroxy-9,10-anthracenedione
banoxantrone [inn]
SCHEMBL3676563
DB04975
YZBAXVICWUUHGG-UHFFFAOYSA-N
2-[[4-[2-[dimethyl(oxido)azaniumyl]ethylamino]-5,8-dihydroxy-9,10-dioxoanthracen-1-yl]amino]-n,n-dimethylethanamine oxide
Q27292332
2,2'-(5,8-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-1,4-diyl)bis(azanediyl)bis(n,n-dimethylethanamine oxide)
banoxantrone (aq4n)
DTXSID90869860
CS-0007169
HY-13562

Research Excerpts

Overview

AQ4N is a prodrug activated under hypoxic conditions to AQ4, which is structurally similar to mitoxantrone and inhibits topoisomerase II. AQ4N can significantly enhance the anti-tumour effect of radiation and cyclophosphamide.

Excerpt	Reference	Relevance
"AQ4N is a novel prodrug that is selectively bioreduced to AQ4, a topoisomerase II inhibitor, in hypoxic tumor. "	( A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Beeram, M; Desai, K; Goel, S; Haigentz, M; Lalani, AS; Mani, S; Milián, ML; Papadopoulos, KP; Sarantopoulos, J; Tolcher, A; Wong, A, 2008)	2.01
"AQ4N is a prodrug activated under hypoxic conditions to AQ4, which is structurally similar to mitoxantrone and inhibits topoisomerase II."	( The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Garbens, AB; Lalani, AS; Tannock, IF; Trédan, O, 2009)	1.36
"AQ4N is a novel bioreductive prodrug under clinical investigation. "	( Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Albertella, MR; Alcock, C; Anthoney, A; Burnet, N; Dunk, CR; Harris, PA; Jones, PH; Lalani, AS; Loadman, PM; Phillips, RM; Rampling, R; Twelves, CJ; Vjaters, E; Wong, A, 2008)	2.03
"AQ4N is a bioreductive alkylaminoanthraquinone that is cytotoxic when reduced to AQ4; hence, it can be used to target hypoxic tumor cells."	( Evaluation of the antiangiogenic potential of AQ4N. Hirst, DG; McKenna, J; McKeown, SR; O'Rourke, M; Robson, T; Valentine, A; Ward, C; Worthington, J, 2008)	1.33
"AQ4N is a bioreductive prodrug of a potent, stable, reduction product which binds non-covalently to DNA, facilitating antitumour activity in both hypoxic and proximate oxic tumour cells."	( AQ4N: a new approach to hypoxia-activated cancer chemotherapy. McKeown, SR; Patterson, LH, 2000)	2.47
"AQ4N is a bioreductive drug that can significantly enhance the anti-tumour effect of radiation and cyclophosphamide. "	( The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Friery, OP; Gallagher, R; Hirst, DG; Hughes, CM; McKeown, SR; Murray, MM; Patterson, LH, 2001)	1.99

Pharmacokinetics

Excerpt	Reference	Relevance
" There was a linear increase in the maximum plasma concentration (Cmax) proportional to dose with a Cmax of 1171 microg/ml at the maximum tolerated dose of 200 mg/kg."	( A preclinical pharmacokinetic study of the bioreductive drug AQ4N. Bibby, MC; Loadman, PM; Patterson, LH; Swaine, DJ; Welham, KJ, 2001)	0.55

Compound-Compound Interactions

AQ4N (100 mg/kg) and 10 Gy X-rays were used to control tumours. A single injection of CYP3A4 into established RIF-1 murine tumors increased AQ4N metabolism. Three of nine tumors were locally controlled for >60 days.

Excerpt	Reference	Relevance
" AQ4N in combination with single dose radiation (12 Gy) and also with two fractionated radiation regimens was examined (5 x 3 Gy, one fraction per day; or 10 x 2 Gy fractions, 2 fractions per day with an 8 h interval)."	( Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Friery, OP; Hejmadi, MV; Hirst, DG; McIntyre, IA; McKeown, SR; Patterson, LH, 1996)	1.48
" A single injection of CYP3A4 into established RIF-1 murine tumors increased the metabolism of AQ4N, and when used in combination with radiation, three of nine tumors were locally controlled for >60 days."	( Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Hirst, DG; Hughes, CM; Keilty, G; McCarthy, HO; McErlane, V; McKeown, SR; Murray, M; Patterson, LH; Robson, T; Yakkundi, A, 2003)	0.78
" In vivo, a single intra-tumoural injection of a CYP2B6 vector construct significantly enhanced tumour growth delay in combination with AQ4N (100 mg/kg) and 10 Gy X-rays."	( A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. Hirst, DG; Hughes, CM; McCarthy, HO; McErlane, V; McKeown, SR; Patterson, LH; Robson, T; Yakkundi, A, 2005)	0.73

Bioavailability

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	14.7118	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Nitric oxide synthase, inducible	Homo sapiens (human)	Km	130.0000	2.8000	5.7000	8.6000	AID362521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
response to hypoxia	Nitric oxide synthase, inducible	Homo sapiens (human)
positive regulation of leukocyte mediated cytotoxicity	Nitric oxide synthase, inducible	Homo sapiens (human)
innate immune response in mucosa	Nitric oxide synthase, inducible	Homo sapiens (human)
arginine catabolic process	Nitric oxide synthase, inducible	Homo sapiens (human)
superoxide metabolic process	Nitric oxide synthase, inducible	Homo sapiens (human)
nitric oxide biosynthetic process	Nitric oxide synthase, inducible	Homo sapiens (human)
circadian rhythm	Nitric oxide synthase, inducible	Homo sapiens (human)
response to bacterium	Nitric oxide synthase, inducible	Homo sapiens (human)
negative regulation of gene expression	Nitric oxide synthase, inducible	Homo sapiens (human)
peptidyl-cysteine S-nitrosylation	Nitric oxide synthase, inducible	Homo sapiens (human)
prostaglandin secretion	Nitric oxide synthase, inducible	Homo sapiens (human)
positive regulation of interleukin-6 production	Nitric oxide synthase, inducible	Homo sapiens (human)
positive regulation of interleukin-8 production	Nitric oxide synthase, inducible	Homo sapiens (human)
regulation of cell population proliferation	Nitric oxide synthase, inducible	Homo sapiens (human)
negative regulation of protein catabolic process	Nitric oxide synthase, inducible	Homo sapiens (human)
defense response to bacterium	Nitric oxide synthase, inducible	Homo sapiens (human)
regulation of cellular respiration	Nitric oxide synthase, inducible	Homo sapiens (human)
cell redox homeostasis	Nitric oxide synthase, inducible	Homo sapiens (human)
regulation of insulin secretion	Nitric oxide synthase, inducible	Homo sapiens (human)
defense response to Gram-negative bacterium	Nitric oxide synthase, inducible	Homo sapiens (human)
positive regulation of killing of cells of another organism	Nitric oxide synthase, inducible	Homo sapiens (human)
cellular response to lipopolysaccharide	Nitric oxide synthase, inducible	Homo sapiens (human)
cellular response to type II interferon	Nitric oxide synthase, inducible	Homo sapiens (human)
cellular response to xenobiotic stimulus	Nitric oxide synthase, inducible	Homo sapiens (human)
regulation of cytokine production involved in inflammatory response	Nitric oxide synthase, inducible	Homo sapiens (human)
negative regulation of blood pressure	Nitric oxide synthase, inducible	Homo sapiens (human)
response to hormone	Nitric oxide synthase, inducible	Homo sapiens (human)
nitric oxide mediated signal transduction	Nitric oxide synthase, inducible	Homo sapiens (human)
response to lipopolysaccharide	Nitric oxide synthase, inducible	Homo sapiens (human)
inflammatory response	Nitric oxide synthase, inducible	Homo sapiens (human)
positive regulation of guanylate cyclase activity	Nitric oxide synthase, inducible	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nitric-oxide synthase activity	Nitric oxide synthase, inducible	Homo sapiens (human)
protein binding	Nitric oxide synthase, inducible	Homo sapiens (human)
calmodulin binding	Nitric oxide synthase, inducible	Homo sapiens (human)
FMN binding	Nitric oxide synthase, inducible	Homo sapiens (human)
heme binding	Nitric oxide synthase, inducible	Homo sapiens (human)
tetrahydrobiopterin binding	Nitric oxide synthase, inducible	Homo sapiens (human)
arginine binding	Nitric oxide synthase, inducible	Homo sapiens (human)
protein homodimerization activity	Nitric oxide synthase, inducible	Homo sapiens (human)
metal ion binding	Nitric oxide synthase, inducible	Homo sapiens (human)
flavin adenine dinucleotide binding	Nitric oxide synthase, inducible	Homo sapiens (human)
NADP binding	Nitric oxide synthase, inducible	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Nitric oxide synthase, inducible	Homo sapiens (human)
nucleoplasm	Nitric oxide synthase, inducible	Homo sapiens (human)
cytoplasm	Nitric oxide synthase, inducible	Homo sapiens (human)
peroxisome	Nitric oxide synthase, inducible	Homo sapiens (human)
peroxisomal matrix	Nitric oxide synthase, inducible	Homo sapiens (human)
cytosol	Nitric oxide synthase, inducible	Homo sapiens (human)
cortical cytoskeleton	Nitric oxide synthase, inducible	Homo sapiens (human)
perinuclear region of cytoplasm	Nitric oxide synthase, inducible	Homo sapiens (human)
plasma membrane	Nitric oxide synthase, inducible	Homo sapiens (human)
nucleus	Nitric oxide synthase, inducible	Homo sapiens (human)
cytosol	Nitric oxide synthase, inducible	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (59)

Assay ID	Title	Year	Journal	Article
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID124098	in vivo activity against aerobic and hypoxic cells in RIF-1 tumors when administered at a dose of 225 umol/kg in mice 30 min before exposure to radiation	2001	Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21	Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
AID362521	Activity of human recombinant iNOS expressed in Escherichia coli assessed as 1-{[2-(dimethylamino-N-oxide)ethyl]amino}-4-{[2-(dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione level	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase.
AID115134	In vivo toxicity against C3H/HeN cell line in mice expressed as maximal tolerated dose	2001	Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21	Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
AID362526	Inhibition of human recombinant iNOS expressed in Escherichia coli assessed as 1,4-bis-{[2-(dimethylamino-N-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione reduction after 60 mins in presence of econazole	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase.
AID362525	Activity of human recombinant iNOS expressed in Escherichia coli assessed as 1-{[2-(dimethylamino-N-oxide)ethyl]amino}-4-{[2-(dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione level at 1 uM in presence of arginine	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase.
AID362523	Inhibition of human recombinant iNOS expressed in Escherichia coli assessed as 1,4-bis-{[2-(dimethylamino-N-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione reduction after 60 mins in presence of clotrimazole	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase.
AID124099	in vivo activity against aerobic and hypoxic cells in RIF-1 tumors when administered at a dose of 225 umol/kg in mice after 5 min of exposure to radiation	2001	Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21	Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
AID124097	in vivo activity against aerobic and hypoxic cells in RIF-1 tumors when administered at a dose of 225 umol/kg in mice	2001	Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21	Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
AID362524	Inhibition of human recombinant iNOS expressed in Escherichia coli assessed as 1,4-bis-{[2-(dimethylamino-N-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione reduction after 60 mins in presence of ketoconazole	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	9 (13.43)	18.2507
2000's	28 (41.79)	29.6817
2010's	15 (22.39)	24.3611
2020's	15 (22.39)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (4.48%)	5.53%
Reviews	9 (13.43%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	55 (82.09%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 1, Open-Label, Dose-Escalation Study of AQ4N Administered Intravenously in Patients With Advanced Malignancies [NCT00090727]	Phase 1	45 participants	Interventional	2004-08-31	Active, not recruiting
A Phase 1/2, Open Label, Dose Escalation Study of AQ4N for Safety, Tolerability, Pharmacokinetics and Activity in Patients With Lymphoid Neoplasms [NCT00109356]	Phase 1/Phase 2	55 participants	Interventional	2005-03-31	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Classes	Roles
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	2.21	1	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	2.08	1	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	7.17	1
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	2.08	1	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
mechlorethamine nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.	2	1	nitrogen mustard; organochlorine compound	alkylating agent
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	7.42	2	dihydroxyanthraquinone	analgesic; antineoplastic agent
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.21	1	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
krypton Krypton: A noble gas that is found in the atmosphere. It has the atomic symbol Kr, atomic number 36, atomic weight 83.80, and has been used in electric bulbs.	1.99	1	monoatomic krypton; noble gas atom; p-block element atom
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	4.05	2	mitomycin	alkylating agent; antineoplastic agent
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	2.04	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	1.99	1	xanthene
acridines Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.	1.99	1	acridines; mancude organic heterotricyclic parent; polycyclic heteroarene	genotoxin
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	2.08	1	indazole
gluconic acid gluconic acid: zinc gluconate has anti-inflammatory activity; RN given refers to (D)-isomer; all RRs refers to (D)-isomer unless otherwise noted. ketogluconic acid : A gluconic acid that contains a ketonic carbonyl group.. D-gluconic acid : A gluconic acid having D-configuration.	2.17	1	gluconic acid	chelator; Penicillium metabolite
copper gluconate Gluconates: Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters.	2.17	1	organic molecular entity
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	3.19	1	C-nitro compound; imidazoles	antitubercular agent
porfiromycin Porfiromycin: Toxic antibiotic of the mitomycin group, obtained from MITOMYCIN and also from Streptomyces ardus and other species. It is proposed as an antineoplastic agent, with some antibiotic properties.	2	1
cupric sulfide copper(II) sulfide : A copper sulfide in which the metal is in the +2 oxidation state.	2.15	1
nitracrine Nitracrine: Acridine antineoplastic agent used in mammary and ovarian tumors. It inhibits RNA synthesis.	6.99	1	acridines
titanium Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.	2.31	1	titanium group element atom
gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.	2.15	1	copper group element atom; elemental gold
titanium dioxide titanium dioxide: used medically as protectant against externally caused irritation & sunlight; high concentrations of dust may cause irritation to respiratory tract; RN given refers to titanium oxide (TiO2); structure. titanium dioxide : A titanium oxide with the formula TiO2. A naturally occurring oxide sourced from ilmenite, rutile and anatase, it has a wide range of applications.	2.31	1	titanium oxides	food colouring
fludarabine phosphate fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.	2.13	1	nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate	antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug
vidarabine phosphate Vidarabine Phosphate: An adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of VIDARABINE with antiviral and possibly antineoplastic properties.	2.13	1
tretazicar tretazicar: minor descriptor (75-84); on-line & Index Medicus search AZIRIDINES (75-84)	3.57	2
n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide [no description available]	1.99	1
efaproxiral efaproxiral: RN & structure given in first source; allosteric effector of hemoglobin	3.13	1
vadimezan vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.	1.99	1	monocarboxylic acid; xanthones	antineoplastic agent
4-(3-(2-nitro-1-imidazolyl)-propylamino)-7-chloroquinoline hydrochloride 4-(3-(2-nitro-1-imidazolyl)-propylamino)-7-chloroquinoline hydrochloride: structure in first source	3.13	1
sesquiterpenes [no description available]	2.04	1
apaziquone apaziquone: structure given in first source; RN given refers to (E)-isomer	4.07	2	indoles
axitinib [no description available]	2.08	1	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
fumagillin [no description available]	2.04	1	antibiotic antifungal drug; carboxylic ester; dicarboxylic acid monoester; meroterpenoid; organooxygen heterocyclic antibiotic; spiro-epoxide	angiogenesis inhibitor; antibacterial drug; antimicrobial agent; antiprotozoal drug; fungal metabolite; methionine aminopeptidase 2 inhibitor
lenvatinib lenvatinib : A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.	2.6	1	aromatic amide; aromatic ether; cyclopropanes; monocarboxylic acid amide; monochlorobenzenes; phenylureas; quinolines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist; orphan drug; vascular endothelial growth factor receptor antagonist
motexafin gadolinium [no description available]	3.13	1
pr-104 PR-104: 3,5-dinitrobenzamide nitrogen mustard, an alkyating antineoplastic; structure in first source	3.56	2
indocyanine green Indocyanine Green: A tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output.	2.6	1	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
th 302 TH 302: an hypoxia-activated prodrug of bromo-isophosphoramide mustard; an antineoplastic agent	3.19	1
heme Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.	7.04	1
2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone: structure in first source	3.13	1
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	3.14	1	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
tirapazamine Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.	6.21	11	aromatic amine; benzotriazines; N-oxide	antibacterial agent; antineoplastic agent; apoptosis inducer

Condition	Relationship Strength	Studies	Trials
Congenital Zika Syndrome [description not available]	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.98	4	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1	0
Benign Neoplasms [description not available]	9.2	24	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	9.2	24	2
Anoxemia [description not available]	4.78	10	0
Colorectal Cancer [description not available]	2.61	2	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	9.78	10	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.61	2	0
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	3.01	2	0
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	3.01	2	0
Local Neoplasm Recurrence [description not available]	2.6	1	0
Lymph Node Metastasis [description not available]	2.61	2	0
Breast Cancer [description not available]	3.42	2	0
Breast Neoplasms Tumors or cancer of the human BREAST.	3.42	2	0
Animal Mammary Carcinoma [description not available]	2.46	2	0
Cancer of Lung [description not available]	2.47	2	0
B16 Melanoma [description not available]	2.11	1	0
EHS Tumor [description not available]	2.11	1	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	2.97	4	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.47	2	0
Hepatocellular Carcinoma [description not available]	2.15	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.15	1	0
Lassitude [description not available]	3.43	1	1
Emesis [description not available]	3.43	1	1
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	3.43	1	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	3.43	1	1
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	3.43	1	1
Cancer of Prostate [description not available]	2.46	2	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.46	2	0
Angiogenesis, Pathologic [description not available]	2.08	1	0
Carcinoma, Non-Small Cell Lung [description not available]	2.03	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.03	1	0
Metastase [description not available]	2.03	1	0
Cancer of Pancreas [description not available]	2.44	2	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.03	1	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.44	2	0
Adenocarcinoma, Basal Cell [description not available]	3.42	1	1
Carcinoma, Epidermoid [description not available]	3.42	1	1
Cancer of Esophagus [description not available]	3.42	1	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	3.42	1	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	3.42	1	1
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	3.42	1	1
Choroid Neovascularization [description not available]	2.03	1	0
Neovascularization, Optic Disc [description not available]	2.03	1	0
Retinal Neovascularization Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.	2.03	1	0
Cancer of Colon [description not available]	2.04	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.04	1	0
Experimental Mammary Neoplasms [description not available]	2.91	4	0
Experimental Neoplasms [description not available]	3.6	3	0

aq4n

Description

Cross-References

Synonyms (26)

Research Excerpts

Overview

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Protein Targets (2)

Potency Measurements

Other Measurements

Biological Processes (31)

Molecular Functions (11)

Ceullar Components (9)

Bioassays (59)

Research

Studies (67)

Market Indicators

Research Demand Index: 22.11

Study Types

Clinical Trials (2)

Trial Overview

aq4n

Description

Cross-References

Synonyms (26)

Research Excerpts

Overview

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Protein Targets (2)

Potency Measurements

Other Measurements

Biological Processes (31)

Molecular Functions (11)

Ceullar Components (9)

Bioassays (59)

Research

Studies (67)

Market Indicators

Research Demand Index: 22.11

Study Types

Clinical Trials (2)

Trial Overview

Related Drugs (42)

Related Conditions (50)